The urinary tract infection therapeutic market comprises drugs used for the treatment of various types of urinary tract infections. UTI therapeutic drugs offer effective treatment against both complicated and uncomplicated urinary tract infections by inhibiting the growth of bacteria and clearing the infection. With growing antibiotic resistance contributing to increasing incidence of complicated and recurrent UTIs, demand for advanced UTI therapeutic drugs is rising.
The global Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 8,665.5 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: Growing antibiotic resistance is a major driver of the urinary tract infection therapeutic market. Overuse and misuse of antibiotics has led to emergence of drug-resistant bacterial strains causing UTIs. It is estimated that around 25% of UTIs in the US are resistant to commonly used antibiotics. Treatment of such infections requires options beyond conventional antibiotics. This is promoting research and development of novel drug classes like NAI therapies. For example, EF076 by Entasis Therapeutics is a novel NAI molecule in Phase 3 trials for treatment of multi-drug resistant gram-negative UTIs. Its efficacy against drug-resistant bacteria makes it a promising future therapeutic option.
Strength: Strong pipeline for new drugs to treat urinary tract infections. Growing research and development activities for novel therapies.
Weakness: High treatment cost associated with urinary tract infection treatments. Increase in generic competition eroding market share of branded drugs.
Opportunity: Rising prevalence of urinary tract infections globally driving the need for effective therapeutics. Growing geriatric population susceptible to urinary tract infections.
Threats: Stringent regulatory environment for drug approval. Side effects associated with few antibiotics increasing preference for alternative treatment options.
The global urinary tract infection therapeutic market is expected to witness high growth. The market was valued at US$ 8,665.5 Mn in 2024 and is anticipated to reach US$ 11,852.4 Mn by 2030, expanding at a CAGR of 3.0% during the forecast period.
North America currently dominates the global market and is expected to maintain its leading position throughout the analysis period. This can be attributed to the growing prevalence of urinary tract infections, increasing healthcare spending, and ongoing clinical trials for advanced drugs.
Europe is projected to be the second largest and fastest growing regional market between 2023-2030. Major market growth drivers include rising geriatric population, which are more susceptible to urinary tract infections. Asia Pacific is projected to offer lucrative opportunities owing to increasing access to healthcare facilities and growing awareness about urinary tract infection treatments.
Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. Pfizer leads the global market with its anti-infective portfolio comprising antibiotics like Bactrim and Monurol. Novartis is another major player focusing on research for developing novel antibiotics to treat antibiotic-resistant urinary tract infections.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it